Three amino acids that shut down your body's master inflammation switch — tested only in mice, sold to thousands, and delivered in a form the researchers never used

The human body produces a 13-amino-acid hormone called alpha-melanocyte-stimulating hormone (α-MSH) that does far more than control skin pigmentation. α-MSH is one of the most potent endogenous anti-inflammatory molecules known — and in 2007, researchers demonstrated that most of that anti-inflammatory power could be traced to just the last three amino acids of the molecule: lysine-proline-valine (PMID 17934097). That fragment — KPV — retains the ability to suppress the NF-κB inflammatory signaling pathway at nanomolar concentrations while shedding the melanocortin receptor binding that causes tanning, appetite changes, and sexual side effects.

The pharmacological elegance is real. KPV inhibits NF-κB — arguably the most important inflammatory signaling pathway in the human body, implicated in everything from inflammatory bowel disease to rheumatoid arthritis to cancer progression. It does this at remarkably low concentrations. And it is transported into intestinal cells by PepT1, a peptide transporter that is upregulated precisely in inflamed gut tissue (PMID 18061177), meaning the drug theoretically concentrates exactly where it is needed most during inflammatory bowel disease.

But the distance between elegant pharmacology and proven medicine is vast. No human has ever received KPV in a clinical trial. The entire evidence base consists of mouse colitis models and cell culture experiments, predominantly from one research group. The most impressive preclinical results used a hyaluronic acid nanoparticle delivery system that is not commercially available — what community users purchase is raw KPV powder, not the nanoparticle formulation. The FDA explicitly stated it possesses no human exposure data for KPV and placed it in Category 2 (do not compound) in September 2023. This article explains the immune biology, acknowledges the promise, and maps the gap between laboratory findings and human self-use.

Quick Facts: KPV at a Glance

What Is Kpv?

Pronunciation: kay-pee-vee

Inflammation is not inherently bad — it is how your body fights infection, repairs tissue damage, and clears cellular debris. The problem is when inflammation does not stop. Chronic inflammation — the immune system attacking tissues it should be protecting — drives inflammatory bowel disease, rheumatoid arthritis, psoriasis, atherosclerosis, neurodegeneration, and dozens of other conditions. The molecular machinery that controls this on-off switch is a pathway called NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), and KPV is one of the smallest molecules ever found to shut it down.

KPV is a tripeptide — literally three amino acids: lysine, proline, valine — clipped from the tail end of alpha-melanocyte-stimulating hormone (α-MSH). Alpha-MSH is a 13-amino-acid hormone best known for stimulating melanin production (tanning), but it also has profound anti-inflammatory effects. In 2007, researchers at the University of Colorado demonstrated that most of those anti-inflammatory effects resided in just the last three amino acids — the KPV fragment (PMID 17934097). This was a pharmacologically important discovery: it meant you could separate the anti-inflammatory action of α-MSH from its melanocortin receptor binding. KPV does not activate MC1R through MC5R. It does not cause tanning, appetite changes, or sexual function effects. It targets NF-κB directly.

At nanomolar concentrations — extraordinarily low doses — KPV stabilizes IκBα (the protein that keeps NF-κB sequestered in the cytoplasm) and competitively blocks p65RelA nuclear import (PMID 22837805). When NF-κB cannot enter the nucleus, it cannot activate the genes that produce inflammatory cytokines like TNF-α, IL-1β, IL-6, and IL-8. The master inflammatory switch stays off.

Origins and Discovery

The story of KPV begins with α-MSH — a hormone discovered in the 1950s for its role in stimulating melanocytes (the cells that produce skin pigment). Over the following decades, researchers discovered that α-MSH had potent anti-inflammatory effects that appeared unrelated to its pigmentation activity. The anti-inflammatory properties were mapped to the C-terminal region of the molecule — specifically, the last three amino acids.

The definitive characterization came from work led by Thomas Luger and colleagues, who demonstrated that α-MSH fragments, including KPV, suppressed inflammatory cytokine production in vitro (PMID 12750433). In 2007, a landmark review (PMID 17934097) proposed KPV as a "new class of anti-inflammatory drugs" — small enough to be orally bioavailable via peptide transporters, potent enough to work at nanomolar concentrations, and free of the melanocortin receptor side effects of the parent peptide.

The gut connection emerged in 2008 when Dalmasso et al. at Emory University demonstrated that KPV was transported into intestinal epithelial cells by the PepT1 transporter, and that oral KPV reduced colitis in mice (PMID 18061177). This finding transformed KPV from a general anti-inflammatory curiosity into a targeted gut inflammation candidate — and launched the community enthusiasm that would eventually far outpace the evidence.

Mechanism of Action

NF-κB Suppression — The Master Immune Switch

NF-κB is not just an inflammation pathway — it is arguably the most important transcription factor family in the immune system. It controls the expression of hundreds of genes involved in inflammation, immune cell activation, cell survival, and apoptosis. In the context of immune health, NF-κB is the molecular checkpoint that determines whether an immune response stays proportional or becomes pathological.

KPV suppresses NF-κB activation through at least two mechanisms:

1. IκBα stabilization: In resting cells, NF-κB is held in the cytoplasm by inhibitory proteins called IκBs. Inflammatory signals trigger IκBα phosphorylation and degradation, freeing NF-κB to enter the nucleus. KPV stabilizes IκBα, preventing its degradation and keeping NF-κB sequestered.

2. p65RelA nuclear import blockade: Even when IκBα is partially degraded, KPV competitively blocks the nuclear import of p65RelA (the primary transactivating subunit of NF-κB) via the importin-α3 binding site (PMID 22837805). This provides a second layer of suppression.

The result: downstream inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) are not produced. The inflammatory cascade does not initiate — or if already active, it is dampened.

MAPK/ERK Pathway Inhibition

KPV also reduces signaling through the MAP kinase (MAPK/ERK) pathway, a second major inflammatory signaling cascade. MAPK signaling is involved in cell proliferation, differentiation, and inflammatory gene expression. By inhibiting both NF-κB and MAPK, KPV targets two of the most important inflammatory signaling nodes simultaneously.

PepT1-Mediated Uptake — The Gut-Targeting Mechanism

The PepT1 transporter (SLC15A1) is normally expressed in the small intestine, where it absorbs dietary di- and tripeptides. During inflammatory bowel disease, PepT1 expression is induced in the colon — where it is normally absent. This means that during active IBD, the inflamed colon expresses a transporter that can actively absorb KPV, concentrating the drug precisely in the tissue that needs it most (PMID 18061177).

This pharmacological feature is genuinely elegant: the disease creates the drug delivery mechanism. But it also means KPV's gut-targeting advantage is specific to active IBD — in a healthy colon without PepT1 expression, oral KPV may not achieve meaningful colonic concentrations.

What KPV Does NOT Do

Unlike full-length α-MSH, KPV does not bind melanocortin receptors (MC1R through MC5R). It does not cause skin darkening, appetite changes, sexual function changes, or any of the hormonal effects associated with α-MSH or its synthetic analogs (melanotan I, melanotan II, PT-141). The anti-inflammatory activity of α-MSH is separable from its receptor-mediated effects, and KPV carries only the anti-inflammatory component.

Key Research Areas and Studies

IBD Models — The Core Evidence

The strongest preclinical evidence for KPV comes from rodent models of inflammatory bowel disease:

DSS-Induced Colitis (PMID 18061177, 2008): Oral KPV reduced disease activity index, colonic inflammation, and pro-inflammatory cytokine levels in mice with dextran sodium sulfate-induced colitis. This study also characterized the PepT1 transport mechanism. Key limitation: the study used ~40 mice, and the results have not been replicated in human tissue.

TNBS-Induced Colitis (PMID 18092346, 2007): KPV showed similar protective effects in a different colitis model (trinitrobenzenesulfonic acid-induced). Reduced inflammatory markers and tissue damage.

Nanoparticle-Encapsulated KPV (PMC: 5498804, 2017): Hyaluronic acid nanoparticles loaded with KPV (HA-KPV-NP) showed enhanced anti-colitis effects in mice, combining targeted delivery with the anti-inflammatory payload. This is a critical study because the nanoparticle formulation is NOT what community users purchase — raw KPV powder has different pharmacokinetic properties than HA-KPV-NP.

Broader Immune Modulation

NF-κB Mechanism Characterization (PMID 22837805): Detailed mechanistic work showing KPV stabilizes IκBα and blocks p65RelA nuclear import via importin-α3. This study provides the molecular basis for KPV's anti-inflammatory activity.

Skin Inflammation (PMID 15102092): KPV and ACTH signal in human keratinocytes, suggesting dermatological anti-inflammatory potential beyond the gut.

Antimicrobial Activity (PMID 10670585): α-MSH peptides including the KPV fragment show antimicrobial effects against Candida albicans and Staphylococcus aureus. These effects are modest compared to dedicated antimicrobial peptides like LL-37.

Antifibrotic/Anti-Inflammatory Review (PMC: 7827684, 2021): Comprehensive review of melanocortin peptide anti-inflammatory roles, including KPV, with discussion of potential applications beyond IBD.

The Single-Lab Dominance Problem

A significant portion of the KPV IBD evidence originates from a small number of research groups, primarily based at Emory University. The PepT1 transport discovery, the DSS colitis studies, and the nanoparticle delivery work all trace to overlapping research networks. This does not mean the findings are wrong, but it means they lack independent replication — the most important validation criterion in biomedical science. Internally consistent results from one group are a starting point, not a conclusion.

The Immune-Gut Axis — Why Gut Inflammation Is Immune Dysfunction

To understand why KPV belongs in Cluster F (Immune Health) rather than being purely a gut inflammation compound, it helps to understand the immune-gut axis.

Approximately 70% of your immune system resides in or around the gastrointestinal tract. The gut-associated lymphoid tissue (GALT) — including Peyer's patches, mesenteric lymph nodes, and the intestinal epithelial barrier — represents the largest immune organ in the body. The gut lining is where the immune system makes its most critical decisions: which of the trillions of bacteria, food proteins, and environmental antigens passing through the GI tract are threats, and which are tolerable.

When this decision-making process breaks down, the result is inflammatory bowel disease — an immune system attacking the gut tissue it should be protecting. But the implications extend far beyond the GI tract. Gut barrier dysfunction ("leaky gut") allows bacterial products to enter the bloodstream, triggering systemic inflammation. Dysbiotic gut microbiomes produce metabolites that influence immune cell development throughout the body. And NF-κB — the pathway KPV suppresses — is the master regulator of inflammatory gene expression in immune cells everywhere, not just in the gut.

KPV's anti-inflammatory mechanism (NF-κB suppression) is systemic in principle, even though its best-studied application is gut-specific. If KPV suppresses NF-κB in intestinal epithelial cells, the same mechanism should operate in any NF-κB-expressing cell — which is virtually every cell in the body. The gut-targeting via PepT1 is a delivery advantage for oral administration, not a limitation of the compound's pharmacological activity.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

There is no human evidence landscape for KPV. Zero clinical trials. Zero case series. Zero formal safety studies. Zero human subjects have received exogenous KPV in any published, peer-reviewed context.

This is not a situation where human data is thin or limited — it is genuinely absent. For a compound that thousands of people in self-experimentation communities are using for IBD, gut inflammation, and general immune support, this absence is remarkable and should be the central fact in any informed decision about KPV use.

What Would Need to Happen for Human Evidence to Emerge

For KPV to progress from preclinical to clinical, the following would be required:

1. IND application: A sponsor would need to file an Investigational New Drug application with the FDA (or equivalent agency), including preclinical safety data, manufacturing quality data, and a proposed clinical trial protocol.

2. Phase I safety trial: First-in-human study, typically 20–50 healthy volunteers, establishing safe dose range, pharmacokinetics, and tolerability.

3. Phase II efficacy trial: Controlled study in IBD patients, likely 100–200 subjects, testing specific doses against placebo or active comparator.

4. Phase III confirmatory trial: Large, multicenter, randomized trial establishing efficacy and safety for regulatory approval.

No pharmaceutical company or academic institution has initiated step 1. The nanoparticle formulation — which showed the most impressive preclinical results — would require its own manufacturing and regulatory pathway. The raw KPV sold by peptide vendors has never been submitted for regulatory evaluation.

Safety, Risks, and Limitations

No Human Safety Data

This bears repeating because it is the single most important safety fact about KPV: no published human safety study exists. The FDA's explicit statement: "FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration" and "FDA lacks important information regarding any safety issues raised by KPV."

Theoretical Safety Considerations

NF-κB suppression at systemic levels: NF-κB is not just an inflammatory pathway — it controls immune surveillance against pathogens and cancer cells. Chronic systemic NF-κB suppression could theoretically impair the immune system's ability to detect and respond to infections or malignant transformation. No data exists on this question for KPV specifically, but NF-κB inhibition is a double-edged sword in immunology.

Immunosuppressive effects: Any compound that suppresses inflammatory signaling has the potential to suppress protective immune responses. This is not specific to KPV — it is a pharmacological principle. Whether KPV at achievable doses produces meaningful immunosuppression is unknown.

Drug interactions: Unknown. KPV has not been studied in combination with any other drug. Patients on immunosuppressive medications (common in IBD) who add KPV are combining two NF-κB-modulating agents without any safety data on the interaction.

Formulation mismatch: Community users purchasing raw KPV powder are receiving a fundamentally different product than the HA-KPV-NP nanoparticle formulation used in the most impressive preclinical studies. The nanoparticle encapsulation affects bioavailability, tissue distribution, and drug release kinetics. Extrapolating efficacy data from nanoparticle studies to raw powder is pharmacologically unsound.

Tripeptide stability: Native KPV has very low stability — it degrades to constituent amino acids within 24 hours in solution. The acetylated/amidated form (Ac-KPV-NH₂) is more stable but still vulnerable to peptidase degradation. Whether community-purchased KPV maintains potency through reconstitution, storage, and administration is unknown.

Legal and Regulatory Status

FDA Status: Not approved for any indication. Placed in Category 2 (do not compound) in September 2023, alongside 18 other peptides. The FDA's reasoning cited the absence of human exposure data and insufficient safety information. The February 2026 HHS announcement indicated potential reclassification of approximately 14 Category 2 peptides back to Category 1 (compoundable), with KPV reportedly among the candidates. Final disposition is pending as of April 2026.

International: No regulatory approval in any jurisdiction for any indication.

WADA Status: Not specifically listed on the WADA Prohibited List. As a small endogenous peptide fragment without melanocortin receptor activity, KPV is unlikely to be flagged under current WADA categories. Athletes should verify independently through the annual Prohibited List.

Compounding Access (US): Category 2 since September 2023 — not available through 503A or 503B compounding pharmacies. Gray-market peptide vendors remain a source, but product quality, purity, and identity are unregulated.

Research Protocols and Formulation Considerations

Preclinical Protocols

The DSS colitis studies (PMID 18061177) used oral KPV administered to mice at various concentrations in drinking water. The nanoparticle studies (PMC: 5498804) used hyaluronic acid-encapsulated KPV nanoparticles (HA-KPV-NP) administered orally.

Formulation Considerations

• Form: Typically supplied as lyophilized powder (research grade). Available as both native KPV and Ac-KPV-NH₂ (acetylated N-terminus, amidated C-terminus — more stable).
• Reconstitution: Bacteriostatic water for injection (SC use) or dissolved in solution for oral capsules.
• Storage: 2–8°C (36–46°F) for reconstituted solution. Lyophilized powder more stable at -20°C. Native KPV degrades within 24 hours in solution — the Ac-KPV-NH₂ form is preferred.
• Stability concern: Tripeptides are inherently vulnerable to peptidase degradation. The nanoparticle encapsulation used in preclinical studies was designed specifically to protect KPV from degradation — raw powder does not have this protection.
• For detailed reconstitution protocols, see Peptidings [Reconstitution Guide](/guides/reconstitution/)
• For storage best practices, see Peptidings [Storage Guide](/guides/storage/)

Dosing in Published Research

The following table summarizes dosing protocols for KPV as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Published Preclinical Dosing (Animal Only)

No human dosing data exists. Any doses used in community settings are extrapolated from mouse studies or derived from community experimentation without published clinical basis.

Dosing in Self-Experimentation Communities

Community Protocols — Observation, Not Endorsement

The Route Paradox

The published preclinical evidence supports oral delivery — specifically because KPV's pharmacological advantage is gut-targeting via PepT1 transport. Subcutaneous injection bypasses this mechanism entirely. Community users who inject KPV are not using the compound the way it was designed to work. If the PepT1 story is what makes KPV interesting, then injecting it is pharmacologically incoherent.

Combination Stacks

Research into KPV combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining KPV with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Compound	Type	Primary Target	Half-Life	FDA Status	WADA Status	Evidence Tier	Primary Tissue Target	Route	Human Evidence Status	Key Differentiator
BPC-157	Synthetic pentadecapeptide (15 amino acids, derived from gastric protective protein BPC)	VEGF / Nitric oxide (proposed multi-target)	~2–6 hours	Not FDA-approved	Prohibited — S0 (Non-Approved Substances)	Tier 3 — Pilot / Limited Human Data	Musculoskeletal, tendon, ligament, GI tract, CNS	Subcutaneous injection + Oral (both routes studied)	3 published human pilot studies (~30 subjects combined); no RCTs	Broadest tissue tropism in cluster. Only injury-repair peptide with both oral and injectable evidence. Most evidence in rodent models
TB-500	Synthetic 4-amino-acid fragment (residues 17–23 of Thymosin Beta-4)	Actin binding (cell migration, angiogenesis)	~2–3 hours	Not FDA-approved	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 4 — Preclinical Only	Musculoskeletal (muscle, tendon, ligament), cardiac, neurological	Subcutaneous injection	Zero published human clinical trials; animal models and cell culture only	Smallest fragment studied; synthetic derivative of endogenous Thymosin Beta-4. Actin sequestration may drive cell migration
Thymosin Beta-4	Endogenous 43-amino-acid peptide (ubiquitous actin-sequestering protein)	Actin binding, cell migration, angiogenesis	~2–4 hours	Not FDA-approved	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 3 — Pilot / Limited Human Data	Broad: muscle, cardiac, neurological, immune, epithelial	Subcutaneous injection + Topical (cosmetics)	Few human studies; cardiac regeneration in early-stage human data; cosmetic formulations	Full-length parent peptide of TB-500. Endogenous compound; ubiquitous in mammalian tissues. More potent than TB-500 fragment in vitro
GHK-Cu	Synthetic tripeptide-copper complex (Gly-His-Lys chelated to Cu2+)	Collagen synthesis, wound healing, TGF-beta modulation	~2 hours topical; ~4–6 hours systemic (estimated)	Not FDA-approved (topical in cosmetics; injectable investigational)	Prohibited — S0 (injectable as growth factor analog); topical unregulated	Tier 5 — It's Complicated	Dermal (collagen, elastin remodeling); broad systemic effects proposed but unverified	Topical (cosmetics — extensive evidence) vs. Subcutaneous injection (preclinical only)	Topical: 30+ years cosmetic use data; Injectable: zero human trials	Route-dependent evidence: topical skin rejuvenation well-established, but injectable claims extrapolate from fundamentally different delivery
AHK-Cu	Synthetic copper tripeptide variant (Ala-His-Lys chelated to Cu2+)	Copper chelation, extracellular matrix remodeling, growth factor signaling	~2–4 hours (estimated)	Not FDA-approved	Not WADA-listed	Tier 4 — Preclinical Only	Dermal (hair follicle, scalp), cosmetic	Topical (cosmetics)	No human clinical trials; in vitro and cosmetic formulation data only	GHK-Cu structural analog with alanine substitution. Primarily studied for hair growth. Less evidence base than GHK-Cu
LL-37	Human cathelicidin antimicrobial peptide (37 amino acids)	Antimicrobial, wound healing, angiogenesis, vitamin D-regulated immune modulation	~2–4 hours	Not FDA-approved	Not WADA-listed	Tier 3 — Pilot / Limited Human Data	Skin, mucosal surfaces, immune system	Subcutaneous injection, Topical	Limited human data; antimicrobial efficacy well-characterized in vitro; wound healing in animal models	Endogenous host defense peptide. Dual role: direct antimicrobial activity + immune modulation. Vitamin D pathway regulates expression
KPV	Alpha-MSH C-terminal tripeptide (Lys-Pro-Val)	NF-kB inhibition, anti-inflammatory (no melanocortin receptor activation)	~1–2 hours (estimated)	Not FDA-approved	Not WADA-listed	Tier 4 — Preclinical Only	GI tract (colitis models), skin, immune system	Subcutaneous injection, Oral (investigational)	No published human clinical trials; animal models (colitis, dermatitis) only	Smallest anti-inflammatory peptide in cluster (3 amino acids). NF-kB pathway without melanocortin receptor binding. GI-focused research
VIP	Endogenous 28-amino-acid neuropeptide (vasoactive intestinal peptide)	VPAC1/VPAC2 receptor agonism; vasodilation, immunomodulation, bronchodilation	~1–2 minutes (extremely short)	Not FDA-approved (aviptadil in clinical trials)	Not WADA-listed	Tier 2 — Clinical Trials	Pulmonary, GI tract, immune system, neurological	Subcutaneous injection, IV infusion, Intranasal	Multiple Phase 2 trials (ARDS, pulmonary hypertension, sarcoidosis); aviptadil in FDA pipeline	Shortest half-life in cluster. CIRS protocol use. Aviptadil (synthetic VIP) is furthest along FDA pathway among non-approved compounds here
KGF / Palifermin	Recombinant keratinocyte growth factor (FGF-7)	FGFR2b receptor; keratinocyte proliferation, epithelial barrier repair	~3–5 hours	FDA-approved (Kepivance for oral mucositis)	Not WADA-listed	Tier 1 — Approved Drug	Epithelial surfaces (oral mucosa, GI tract, skin)	Intravenous injection (FDA-approved route)	FDA-approved for chemo-induced oral mucositis; multiple Phase 2/3 trials	Only FDA-approved compound in Cluster B. Specific to epithelial tissues. IV-only approved route limits off-label accessibility
Substance P	Endogenous 11-amino-acid tachykinin neuropeptide	NK1 receptor agonism; fibroblast migration, angiogenesis, immune activation	~1–2 minutes	Not FDA-approved	Not WADA-listed	Tier 3 — Pilot / Limited Human Data	Corneal epithelium, skin, nervous system	Topical (corneal), Subcutaneous injection	Human data primarily in corneal wound healing; limited systemic human studies	Endogenous pain signaling peptide repurposed for tissue repair. Strongest human evidence in corneal healing. Dual role: nociception + repair
PRP	Autologous platelet-rich plasma (concentrated growth factor preparation)	PDGF, VEGF, TGF-beta release via platelet degranulation	N/A (not a single molecule)	FDA-cleared devices (not drug-approved)	Prohibited — M1 (Manipulation of Blood and Blood Components)	Tier 2 — Clinical Trials	Musculoskeletal (tendon, cartilage, bone), dermal, hair	Injection (local to injury site)	Hundreds of RCTs across orthopedic, dermatologic, and dental applications	Non-peptide. Autologous preparation — no synthetic manufacturing. Largest clinical evidence base in cluster but high study heterogeneity
ARA-290	Synthetic 11-amino-acid peptide (cibinetide; EPO-derived tissue-protective peptide)	Innate Repair Receptor (EPOR/CD131 heterodimer) selective agonist	~2–4 hours	Not FDA-approved (Phase 2b completed)	Not WADA-listed	Tier 2 — Clinical Trials	Peripheral nerves, retina, cardiac, immune system	Subcutaneous injection (1–8 mg daily in trials); IV infusion (early trials)	Phase 2b complete (sarcoidosis SFN — DOSARA trial); Phase 2 (diabetic neuropathy, diabetic macular edema)	EPO-derived but does NOT bind classical EPO receptor. No erythropoietic activity. Tissue protection without blood doping risk. Furthest clinical development for neuropathy

Compound	Type	Evidence Tier	Verdict	Mechanism	Primary Use Case	Human Data	FDA Status	WADA Status	Key Limitation
Thymosin Alpha-1	28-amino-acid peptide (thymus gland derivative)	Tier 1 — Approved Drug	Strong Foundation	Dendritic cell maturation + T-cell differentiation (Th1/Th17/Treg balance) + NK cell activation + TLR signaling enhancement; bidirectional immune modulation	Immune modulation; hepatitis B/C adjunct; vaccine enhancement; cancer immunotherapy adjunct	>11,000 in 30+ trials (Phase III TESTS sepsis N=3,600; HBV meta-analyses; adjuvant cancer trials)	Approved as Zadaxin in 35+ countries (NOT US/EU); US Category 2 compounding	Not specifically named; thymic peptides not prohibited	US access barrier (Category 2 compounding only); TESTS Phase III sepsis trial negative; evidence concentrated in Chinese/Italian institutions; geographic publication bias
LL-37	37-amino-acid peptide (human cathelicidin — only human member)	Tier 3 — Pilot / Limited Human Data	Eyes Open	Direct membrane disruption of pathogens + chemokine-like immune cell recruitment + TLR modulation + angiogenesis + wound healing via keratinocyte/fibroblast migration; vitamin D–regulated expression via CAMP gene	Innate immune defense; wound healing; antimicrobial; anti-biofilm	~74 across 2 small RCTs (venous leg ulcers N=34; diabetic foot ulcers N≈40) — all topical wound healing	Not approved	Not specifically prohibited	Cancer paradox (pro-tumorigenic at ~5 μg/mL in multiple cancers); route problem (injection destroys membrane-disruption advantage); two tiny topical RCTs only; no systemic human dosing data
KPV	Tripeptide (Lys-Pro-Val — C-terminal fragment of α-MSH)	Tier 4 — Preclinical Only	Thin Ice	NF-κB suppression at nanomolar concentrations + MAPK/ERK inhibition + PepT1-mediated intestinal uptake (transporter upregulated during IBD); does NOT bind melanocortin receptors	Anti-inflammatory; IBD/gut inflammation; immune modulation	None — zero human studies	Not approved	Not specifically prohibited	Zero human data; single research group dominance; nanoparticle formulation used in best studies not commercially available; raw peptide ≠ study formulation; route paradox (injection bypasses PepT1 gut transport)

Related Compounds: How KPV Compares

KPV belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Immune Health cluster.

Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.

Compound	Type	Evidence Tier	Verdict	Mechanism	Primary Use Case	Human Data	FDA Status	WADA Status	Key Limitation
Thymosin Alpha-1	28-amino-acid peptide (thymus gland derivative)	Tier 1 — Approved Drug	Strong Foundation	Dendritic cell maturation + T-cell differentiation (Th1/Th17/Treg balance) + NK cell activation + TLR signaling enhancement; bidirectional immune modulation	Immune modulation; hepatitis B/C adjunct; vaccine enhancement; cancer immunotherapy adjunct	>11,000 in 30+ trials (Phase III TESTS sepsis N=3,600; HBV meta-analyses; adjuvant cancer trials)	Approved as Zadaxin in 35+ countries (NOT US/EU); US Category 2 compounding	Not specifically named; thymic peptides not prohibited	US access barrier (Category 2 compounding only); TESTS Phase III sepsis trial negative; evidence concentrated in Chinese/Italian institutions; geographic publication bias
LL-37	37-amino-acid peptide (human cathelicidin — only human member)	Tier 3 — Pilot / Limited Human Data	Eyes Open	Direct membrane disruption of pathogens + chemokine-like immune cell recruitment + TLR modulation + angiogenesis + wound healing via keratinocyte/fibroblast migration; vitamin D–regulated expression via CAMP gene	Innate immune defense; wound healing; antimicrobial; anti-biofilm	~74 across 2 small RCTs (venous leg ulcers N=34; diabetic foot ulcers N≈40) — all topical wound healing	Not approved	Not specifically prohibited	Cancer paradox (pro-tumorigenic at ~5 μg/mL in multiple cancers); route problem (injection destroys membrane-disruption advantage); two tiny topical RCTs only; no systemic human dosing data
KPV	Tripeptide (Lys-Pro-Val — C-terminal fragment of α-MSH)	Tier 4 — Preclinical Only	Thin Ice	NF-κB suppression at nanomolar concentrations + MAPK/ERK inhibition + PepT1-mediated intestinal uptake (transporter upregulated during IBD); does NOT bind melanocortin receptors	Anti-inflammatory; IBD/gut inflammation; immune modulation	None — zero human studies	Not approved	Not specifically prohibited	Zero human data; single research group dominance; nanoparticle formulation used in best studies not commercially available; raw peptide ≠ study formulation; route paradox (injection bypasses PepT1 gut transport)

Frequently Asked Questions

Summary of Key Findings

KPV is a pharmacologically elegant compound with a genuine claim to scientific interest: a tiny tripeptide that suppresses the master inflammatory pathway (NF-κB) at nanomolar concentrations, delivered to inflamed gut tissue through a transporter (PepT1) that the disease itself upregulates. The science is internally consistent and mechanistically clean.

1. The mechanism is real and well-characterized. NF-κB suppression via IκBα stabilization and p65RelA nuclear import blockade at nanomolar concentrations. MAPK pathway inhibition provides a second anti-inflammatory arm. These are robust in vitro findings.

2. The PepT1 transport story is pharmacologically elegant. Active IBD upregulates PepT1 in the colon, creating a disease-specific drug delivery mechanism for oral KPV. This is genuine pharmacological sophistication — if it translates to humans.

3. Zero human evidence. No clinical trial. No safety study. No pharmacokinetic study. No case series. The FDA states it has no human exposure data. This is not "limited evidence" — it is absent evidence.

4. Single-lab dominance. The core IBD evidence traces to overlapping research networks. Independent replication is lacking.

5. The formulation gap is critical. The strongest preclinical results used nanoparticle-encapsulated KPV that is not commercially available. Community users receive raw peptide with different stability, bioavailability, and delivery characteristics.

6. The route paradox undermines community practice. KPV's pharmacological rationale is oral gut-targeting via PepT1. Subcutaneous injection bypasses this mechanism entirely. Injecting KPV works against the compound's design.

7. Immune implications extend beyond the gut. NF-κB controls inflammation body-wide. The immune-gut axis means gut inflammation has systemic immune consequences. KPV's mechanism is not gut-limited — it is gut-concentrated.

Verdict Recapitulation

KPV earns Tier 4 because zero human evidence exists. The Thin Ice verdict reflects the extreme mismatch between community enthusiasm and published data. The evidence-to-hype ratio is the most unfavorable in Cluster F. The mechanism is interesting. The mouse data is encouraging. But mouse data and a PepT1 story do not constitute evidence that KPV is safe or effective in humans.

For readers considering KPV, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source KPV

Further Reading and Resources

If you want to go deeper on KPV, the evidence landscape for immune health peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Immune Health Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: KPV — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Dalmasso G, et al. (2008). "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. PMID 18061177
2. Dalmasso G, et al. (2007). "Anti-inflammatory peptide KPV reduces mucosal inflammation." PMID 18092346
3. Luger TA, et al. (2007). "α-MSH peptides as a new class of anti-inflammatory drugs." Annals of the New York Academy of Sciences. PMID 17934097
4. Xiao B, et al. (2017). "Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy." Nanomedicine. PMC: 5498804
5. Kannengiesser K, et al. (2008). "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflammatory Bowel Diseases. PMID 18286643
6. Brzoska T, et al. (2003). "α-MSH and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo." PMID 12750433
7. Ichiyama T, et al. (2000). "α-MSH and related tripeptides: antimicrobial effects." PMID 10670585
8. Bohm M, et al. (2004). "KPV and ACTH signaling in human keratinocytes." PMID 15102092
9. Böhm M, Luger TA (2021). "α-MSH anti-inflammatory and antifibrotic roles." PMC: 7827684
10. Zhao Y, et al. (2018). "NF-κB nuclear import blockade by KPV via importin-α3." PMID 22837805

---